Thursday 28. October 2021
2012

COMECE welcomes today’s announcement of the Nobel Prize for Medicine for research on alternatives to embryonic stem cells research

 

The Nobel Prize in Physiology or Medicine 2012 was awarded jointly to John B Gurdon (UK) and Shinya Yamanaka (Japan) "for the discovery that mature cells can be reprogrammed to become pluripotent". This is an important milestone in recognising the key role that non-embryonic stem cells play in the development of new, medical therapies, as alternatives to human embryonic stem cells (hESC). Accordingly, in the ambit of the new Horizon 2020 Research Programme, funding should be redirected from ethically-problematic and scientifically and economically less promising hESC research to non-embryonic stem cell research

 

From the scientific point of view, hESC have been so far rather disappointing, less and less fulfilling clinical promise. It is noteworthy that recently GeronCorp., the world’s leading embryo research company, announced it was closing down its stem cell programme.

 

In contrast, there have been continuing scientific advances in fields of research involving alternative stem cells (adult, derived from umbilical cord or induced pluripotent) which present better prospects for clinical applications; or have indeed already demonstrated widespread clinical results (and do not raise any special ethical problems). Today’s Nobel Prize rewards such efforts to discover alternatives to hESC in mature, specialised cells that once reprogrammed become immature cells capable of developing into any tissues of the body.

 

Furthermore, research on hESC can no longer be patented since the recent ruling of the European Court of Justice in the case of Greenpeace v. Brüstle. The Court clearly defines the human embryo as a human ovum, as soon as fertilized, or as the product of cloning, and confirms that biotechnological inventions using hESC cannot be patented.

 

Despite all these new scientific developments and legal decisions, the European Commission decided to leave open the possibility of funding research on hESC within the Horizon 2020 Research Programme which is currently under discussion in the EU Council and the European Parliament.

 

COMECE requests the EU institutions to adopt a rule laying down that any research entailing the destruction of human embryos or using human embryonic stem cells shall not be funded under Horizon 2020.

 

 

Download COMECE's Position Paper: 18 arguments for making funding of alternative stem cells an EU research policy priority

 

Contact: Johanna Touzel, COMECE Spokesperson and Press Officer

johanna.touzel@comece.eu Tel+32 (0)2 235 05 15

 


COMECE is the Commission of the Bishops’ Conferences of the European Union, and comprises 26 Bishops representing all Member States of the EU. For more than thirty years now, COMECE has been accompanying the process of European integration, and offering its reflections. COMECE is now a partner of the EU institutions in the dialogue foreseen by Article 17 (3) of the Treaty on the Functioning of the EU.

 

Contact presse:

Alessandro Di Maio

Responsable de Presse et Communication E-mail Contact Tel. +32 (0) 2 235 05 15
Contact us
19, Square de Meeûs
B-1050 Bruxelles
T + 32(0)2 235 05 10
Display:
http://www.comece.eu/